XOMA (NASDAQ:XOMA) Upgraded at StockNews.com

StockNews.com upgraded shares of XOMA (NASDAQ:XOMA) from a sell rating to a hold rating in a research note released on Friday.

Separately, HC Wainwright restated a “buy” rating and issued a $104.00 target price on shares of XOMA in a research note on Friday, March 28th.

XOMA Price Performance

NASDAQ XOMA opened at $19.97 on Friday. The company has a market cap of $238.70 million, a PE ratio of -5.74 and a beta of 1.00. The company has a quick ratio of 7.52, a current ratio of 7.52 and a debt-to-equity ratio of 1.28. The firm’s 50-day simple moving average is $22.14 and its two-hundred day simple moving average is $26.21. XOMA has a 52 week low of $18.35 and a 52 week high of $35.00.

XOMA (NASDAQ:XOMA) last released its quarterly earnings data on Monday, March 17th. The biotechnology company reported ($0.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.17). XOMA had a negative net margin of 151.34% and a negative return on equity of 24.95%. The business had revenue of $8.70 million during the quarter, compared to analysts’ expectations of $8.75 million. Research analysts predict that XOMA will post -1.41 earnings per share for the current year.

Insider Buying and Selling

In other XOMA news, major shareholder Bvf Partners L. P/Il sold 500,742 shares of XOMA stock in a transaction dated Friday, January 24th. The stock was sold at an average price of $26.10, for a total transaction of $13,069,366.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CIO Bradley Sitko acquired 2,000 shares of XOMA stock in a transaction dated Monday, April 7th. The shares were purchased at an average price of $24.70 per share, for a total transaction of $49,400.00. Following the completion of the transaction, the executive now directly owns 5,045 shares in the company, valued at approximately $124,611.50. The trade was a 65.68 % increase in their position. The disclosure for this purchase can be found here. Over the last three months, insiders have purchased 29,312 shares of company stock worth $735,061. Insiders own 7.20% of the company’s stock.

Institutional Investors Weigh In On XOMA

A number of hedge funds have recently made changes to their positions in XOMA. BNP Paribas Financial Markets raised its position in XOMA by 95.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company’s stock worth $43,000 after purchasing an additional 795 shares during the period. GAMMA Investing LLC increased its holdings in shares of XOMA by 1,063.8% in the first quarter. GAMMA Investing LLC now owns 1,734 shares of the biotechnology company’s stock worth $35,000 after buying an additional 1,585 shares during the period. New York State Common Retirement Fund increased its holdings in shares of XOMA by 51.2% in the fourth quarter. New York State Common Retirement Fund now owns 2,362 shares of the biotechnology company’s stock worth $62,000 after buying an additional 800 shares during the period. Wells Fargo & Company MN lifted its stake in shares of XOMA by 38.0% in the 4th quarter. Wells Fargo & Company MN now owns 4,300 shares of the biotechnology company’s stock valued at $113,000 after acquiring an additional 1,183 shares during the last quarter. Finally, Bank of America Corp DE boosted its holdings in XOMA by 34.7% during the 4th quarter. Bank of America Corp DE now owns 7,796 shares of the biotechnology company’s stock valued at $205,000 after acquiring an additional 2,009 shares during the period. 95.92% of the stock is currently owned by institutional investors.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.